2020
DOI: 10.1080/14760584.2020.1750375
|View full text |Cite
|
Sign up to set email alerts
|

Progress in the overall understanding of typhoid fever: implications for vaccine development

Abstract: Care's (DHSC) Joint Committee on Vaccination & Immunisation (JCVI) & the European Medicine Agency (EMA) scientific advisory group on vaccines, and is a member of the WHO's Strategic Advisory Group of Experts. The views expressed in this article do not necessarily represent the views of DHSC, JCVI or WHO. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
4
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(4 citation statements)
references
References 124 publications
(119 reference statements)
0
4
0
Order By: Relevance
“…Currently, three kinds of typhoid vaccinations are available for use: live oral Ty21a vaccine, parenteral Vi polysaccharide vaccine, and parenteral typhoid conjugate vaccine (TCV) [ 126 ].…”
Section: Reviewmentioning
confidence: 99%
See 2 more Smart Citations
“…Currently, three kinds of typhoid vaccinations are available for use: live oral Ty21a vaccine, parenteral Vi polysaccharide vaccine, and parenteral typhoid conjugate vaccine (TCV) [ 126 ].…”
Section: Reviewmentioning
confidence: 99%
“…Children aged two to five years old had 80% protection [ 132 ]. The advantages of the Vi vaccine include a low side effect profile and convenience of administration (only one injection) [ 126 ].…”
Section: Reviewmentioning
confidence: 99%
See 1 more Smart Citation
“…Antibiotic resistance for S. Typhi is on the rise in several South Asian countries, with nearly 65% of S. Typhi strains in Pakistan being reported as extensively drug-resistant (XDR) between 2012 and 2018 (5,6). Given the high prevalence of typhoid fever, and increasing antimicrobial resistance, effective vaccination campaigns are needed now more than ever (7,8). In 2018, a Vi-conjugate vaccine (Vi-TCV), which targets the Vi polysaccharide capsule of S. Typhi, was approved by the WHO, and recently demonstrated clinical efficacy of 81.6% in a field study involving over 20,000 Nepalese children (9,10).…”
Section: Introductionmentioning
confidence: 99%